Cite
HARVARD Citation
Reardon, D. et al. (n.d.). ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS. Neuro-oncology. p. vi6. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reardon, D. et al. (n.d.). ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS. Neuro-oncology. p. vi6. [Online].